Related Experiment Video
Updated: Mar 30, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Understanding drugs in breast cancer through drug sensitivity screening
Katharina Uhr1, Wendy J C Prager-van der Smissen1, Anouk A J Heine1
1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, 's-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands.
Abstract:
With substantial numbers of breast tumors showing or acquiring treatment resistance, it is of utmost importance to develop new agents for the treatment of the disease, to know their effectiveness against breast cancer and to understand their relationships with other drugs to best assign the right drug to the right patient. To achieve this goal drug screenings on breast cancer cell lines are a promising approach. In this study a large-scale drug screening of 37 compounds was performed on a panel of 42 breast cancer cell lines representing the main breast cancer subtypes. Clustering, correlation and pathway analyses were used for data analysis. We found that compounds with a related mechanism of action had correlated IC50 values and thus grouped together when the cell lines were hierarchically clustered based on IC50 values. In total we found six clusters of drugs of which five consisted of drugs with related mode of action and one cluster with two drugs not previously connected. In total, 25 correlated and four anti-correlated drug sensitivities were revealed of which only one drug, Sirolimus, showed significantly lower IC50 values in the luminal/ERBB2 breast cancer subtype. We found expected interactions but also discovered new relationships between drugs which might have implications for cancer treatment regimens.
Insights
This study screened 37 drugs across 42 breast cancer cell lines to identify effective treatments. Drug screenings revealed new relationships between compounds, aiding personalized breast cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Breast tumors frequently develop treatment resistance, necessitating novel therapeutic agents.
- Understanding drug effectiveness and interactions is crucial for personalized breast cancer treatment.
Purpose of the Study:
- To conduct a large-scale drug screening on diverse breast cancer cell lines.
- To analyze drug effectiveness and identify potential synergistic or antagonistic interactions.
- To uncover new drug relationships for improved cancer treatment strategies.
Main Methods:
- Performed a large-scale drug screening of 37 compounds on 42 breast cancer cell lines.
- Utilized clustering, correlation, and pathway analyses for data interpretation.
- Hierarchically clustered cell lines based on drug sensitivity (IC50 values).
Main Results:
- Compounds with similar mechanisms of action clustered together based on correlated IC50 values.
- Identified six drug clusters, with five showing related mechanisms of action.
- Revealed 25 correlated and 4 anti-correlated drug sensitivities; Sirolimus showed lower IC50 in luminal/ERBB2 subtype.
Conclusions:
- Drug screening effectively groups compounds by mechanism of action.
- Discovered novel drug interactions with potential clinical implications for breast cancer treatment regimens.
- Findings support the use of drug screenings for personalized medicine in oncology.
